KN069
KN069, dual GLP-1 receptor agonist and GIP receptor antagonist
Written by Aaron CuhaReviewed Sep 2026
Also known as: GLP-1 agonist and GIP antagonist
Mechanistically the opposite of tirzepatide in one molecule, and it also produced weight loss. Its half-life is 37 to 46 days, among the longest of any agent on this site.
Overview
Tirzepatide activates the GIP receptor. This drug blocks it, while activating GLP-1 in the same molecule. Both produce weight loss in humans. If that sounds like it cannot be right, that is the honest state of the field, and this compound is the sharpest single illustration of it.
The first-in-human study in 48 Chinese men with overweight or obesity found dose-dependent weight reduction, with the 90 mg single dose producing minus 4.71 percent at day 7 against minus 0.41 percent on placebo, and effects sustained up to 133 days. That duration comes from an unusual pharmacokinetic profile: total drug half-life of roughly 900 to 1,100 hours, which is 37 to 46 days.
A single dose that is still acting four months later is a different kind of drug from a weekly injection, with a different risk profile, because there is no way to stop it quickly.
Mechanism of action
A single molecule combining GLP-1 receptor agonism with GIP receptor antagonism. The GLP-1 half reduces food intake and improves glycaemic control conventionally. The GIP half blocks a receptor that tirzepatide activates, on the reasoning derived from mouse work that GIP receptor loss protects against diet-induced obesity. Whether agonism and antagonism converge because sustained agonism causes desensitisation that amounts to functional blockade is the leading hypothesis and is not established.
Human evidence
One first-in-human phase 1 in 48 men, reporting dose-dependent weight loss and an extremely long half-life. No phase 2 and no comparison against any active drug.
- 48 participants total: 36 in single ascending dose from 12 to 120 mg and 12 in multiple ascending dose from 15 to 60 mg.
- Well tolerated, with predominantly mild to moderate gastrointestinal adverse events, the expected pattern for GLP-1 receptor agonism.
- Weight change at day 7 on a single 90 mg dose: minus 4.71 percent against minus 0.41 percent on placebo, sustained up to 133 days.
- Multiple-dose 60 mg group reached minus 2.57 percent from baseline at day 25, with a significant waist circumference reduction (p = 0.0446).
- Metabolic markers moved favourably: fasting glucose, triglycerides and uric acid down, insulin and C-peptide up.
- Total-drug half-life 899.74 to 1099.01 hours, roughly 37 to 46 days.
What this does not tell you: 48 men in one country, single and short multiple dosing, with weight as a pharmacodynamic observation rather than a powered endpoint. A day-7 weight change is substantially fluid and gastrointestinal content, not fat. The very long half-life is a genuine safety consideration rather than a selling point: an adverse effect cannot be stopped by stopping the drug, and no long-term data exists. The comparison to tirzepatide is mechanistic, not measured; no head to head exists.
Reading the research record
This compound sits inside an unresolved contradiction that runs through the whole incretin field. Activating the GIP receptor produces weight loss, which is how tirzepatide works. Blocking the GIP receptor also produces weight loss, which is how maridebart cafraglutide works. Both results come from randomised human trials. As of this review two drugs are in phase 2 adding opposite GIP interventions to the same background drug, semaglutide: NNC0480-0389 agonises the receptor and AT673 antagonises it. Proposed explanations exist, including receptor desensitisation under sustained agonism producing functional antagonism, and differing central versus peripheral effects, but none is established. This site reports the paradox rather than resolving it, because nobody has resolved it.
The evidence, charted
Fig. 1 · evidence composition
2of 2 citations (100%) are in people
Every citation cited here is Human work; no other study type is cited on this page. This count is of our own citation list and understates any literature larger than the sources we cite.
Fig. 2 · evidence over time
Every citation here was published in 2026.
Too few distinct publication years on this page to plot as a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Approved
CA
Not approved
Approved in 2 of 4, prescription route in 0, not approved in 2. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Human2026
A phase 1, randomised, double-blind, placebo-controlled trial investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of KN069
First-in-human in Chinese men with overweight or obesity. Single ascending dose 12 to 120 mg, n = 36, randomised 3:1 active to placebo, plus multiple ascending dose n = 12 escalating 15 to 60 mg. Well tolerated with predominantly mild to moderate gastrointestinal adverse events. Dose-proportional exposure from 12 to 90 mg with a total-drug half-life of 899.74 to 1099.01 hours. Maximum early weight change at day 7 on 90 mg was minus 4.71% against minus 0.41% on placebo, sustained up to 133 days. In the multiple-dose part the 60 mg group reached minus 2.57% at day 25 with a significant fall in waist circumference (p = 0.0446). Fasting glucose, triglycerides and uric acid fell and insulin and C-peptide rose.
Diabetes, Obesity and Metabolism - Human2026
A study of KN069 in participants with overweight or obesity
The registry record for the trial above.
ClinicalTrials.gov
Frequently asked questions
How can blocking GIP work if tirzepatide activates it?
Nobody has established the answer, and that is the honest state of the field. Mouse work showed GIP receptor knockout protects against diet-induced obesity, which motivated antagonism. Then tirzepatide, which activates the receptor, became one of the most effective weight loss drugs approved. The leading explanation is that sustained agonism desensitises the receptor and ends up acting like blockade, which would make the two approaches the same thing arriving by different routes. That is a hypothesis.
Is a 37 to 46 day half-life good?
It cuts both ways and the downside gets less attention. Convenience and steady exposure are real advantages. The problem is that if a person reacts badly there is no way to remove the drug, and effects persist for months after the last dose. For a first-in-human compound with 48 participants, that is a reason for more caution than a weekly injection would need.
Is the 4.71 percent weight loss real?
It is a real measurement and it is a day-7 measurement from a single dose in a phase 1 study. Early weight change on these drugs is substantially fluid and reduced gastrointestinal content rather than fat. Judge the compound on a phase 2 body composition result, which does not exist yet.